Empowering Young Adults in Cancer Care: How a New Decision-Making Tool is Changing the Game
"A groundbreaking approach to quantifying patient preferences promises to reshape treatment decisions and improve end-of-life care for young adults facing cancer."
Cancer remains a formidable adversary, particularly for adolescents and young adults (AYAs). Despite advancements in treatment, it remains a leading cause of non-accidental death in this age group. What's more, AYA oncology patients often receive more intensive medical services at the end of life (EOL) compared to younger children and older adults. This highlights a critical need: ensuring that the care provided aligns with their values and preferences.
EOL decision-making is a research priority, largely due to a lack of evidence-based tools that can guide healthcare providers (HCPs) and support patients and families through these challenging times. The complexities of oncology decision-making, compounded by uncertainties about prognosis and the rapid pace of treatment innovations, make it difficult for AYA patients and their parents to navigate the available options.
A groundbreaking study is working to address these challenges by developing a novel tool that quantifies the relative importance of various factors considered by AYA patients, their parents, and healthcare providers when making treatment choices. This approach aims to empower patients, improve communication, and ultimately lead to more goal-concordant care and a reduction in overly intensive EOL interventions.
The AYA Cancer Burden
Adolescents and young adults (AYAs), commonly defined in these sources as people aged 15 to 39, face cancer-related needs that differ from those of children and older adults. The National Cancer Institute identifies chemotherapy, immunotherapy, radiation therapy, stem cell transplants, surgery, and targeted therapy among common treatments. Biomarker testing may help select treatments for some cancers because each person's cancer has a unique biomarker pattern. The National Cancer Institute also notes that treatment options can include standard medical care, while SEER tracks new cases, deaths, and five-year relative survival for this population.
Guidelines and Gaps
The NCCN Guidelines for Adolescent and Young Adult Oncology address risk factors, screening, diagnosis, and survivorship. They are intended to support research into patient-care decisions and clinical questions. However, a recent review reports that standardized guidelines for high-quality AYA care remain lacking despite growing recognition of this population's unique needs. Earlier principles-of-care research also identifies medical, psychosocial, and research barriers that systems must overcome.
The Rise of AYA Oncology
AYA oncology has developed through a series of milestones since the first edition of Cancer in Adolescents and Young Adults was published in 2007. One notable change was expanding the commonly recognized age range from 15–29 to 15–39 years. The field also drew important early momentum from the United Kingdom, where parents and philanthropic advocates helped form Teenage Cancer Trust. Historical accounts describe this movement as a response to inequitable access to expert oncology services designed around AYA needs.
The Conjoint Analysis Revolution: Putting Patient Preferences First
The core of this innovative approach lies in conjoint analysis, a powerful method for understanding how individuals value different attributes of a product or service. In this context, the 'product' is cancer treatment, and the 'attributes' are factors like quality of life, potential side effects, the possibility of a cure, and survival length. Unlike traditional methods that focus on one attribute at a time, conjoint analysis allows for the simultaneous consideration of multiple factors, mirroring the complexity of real-world decisions.
- Comprehensive Assessment: Conjoint analysis considers multiple treatment attributes simultaneously, reflecting the complexity of real-world decisions.
- Preference Quantification: The methodology quantifies the relative importance of each attribute, providing valuable insights into patient priorities.
- Enhanced Communication: The tool facilitates communication between patients, families, and healthcare providers.
- Goal-Concordant Care: The aim is to align treatment decisions with patient preferences, leading to more personalized and effective care.
A Field Still Defining Best Practice
Recent research continues to examine how cancer care can better address the distinct needs of adolescents and young adults. A March 2026 review reports that standardized guidelines for high-quality AYA care remain insufficient despite increasing prevalence and recognition of unique care needs. The Journal of Adolescent and Young Adult Oncology describes itself as the first cancer journal dedicated to all aspects of AYA-aged patients and survivors. Current reviews also cover treatment, follow-up care, coping, psychosocial needs, survivorship, and end-of-life care.
Unequal Access Persists
Recognition of AYA-specific challenges has increased, but access to appropriate care remains uneven. One position statement identifies inequitable access to oncology services that provide expert cancer care and account for AYA needs. A newer analysis argues that cooperation between pediatric and adult oncology services is necessary across the cancer continuum. It presents collaboration as central to improving outcomes and quality of life for AYAs with cancer.
A Distinct Care Population
AYAs occupy a position between pediatric and adult cancer services, so their care may not fit neatly within either established model. Their needs can span medical treatment, psychosocial support, survivorship, and research participation. This suggests that decision-making tools for AYAs should be flexible enough to support individual preferences and care contexts. Without direct comparative evidence in the supplied sources, the relative advantages of specific approaches cannot be determined.
Looking Ahead: Empowering a Vulnerable Population
The MyPref tool represents a significant step forward in empowering AYA patients, their families, and their healthcare providers to make more informed and preference-aligned treatment decisions. By providing a structured way to clarify and communicate values, this approach has the potential to transform the landscape of AYA oncology care, ensuring that these young adults receive the support and respect they deserve during their most challenging times.
From Treatment to Partnership
The available evidence supports viewing AYA cancer care as broader than treatment selection alone. Effective support may need to connect medical, psychosocial, research, survivorship, and end-of-life considerations. A decision-making tool could help organize those considerations, but its value would depend on how well it reflects each young person's circumstances and priorities. The supplied sources do not establish the effectiveness of any particular tool.
Building More Consistent Care
Future progress in AYA oncology will likely require clearer standards and stronger coordination across care settings. Research may also continue expanding the evidence base for psychosocial support, survivorship, and shared decision-making. Because the supplied sources do not identify a specific tool or forecast, these directions should be treated as priorities for further development rather than established outcomes.
Geography and Equity
AYAs face disparities in access to specialized oncology services despite having distinct biological and psychosocial needs. A 2025 report highlights these disparities particularly outside major urban centers in eastern and southern Europe. It argues that addressing geographic inequalities is essential to comprehensive and equitable cancer care. This context shows why a decision-making tool alone may not resolve broader system-level barriers.
Care That Reflects Young Lives
Cancer during adolescence or young adulthood can involve decisions that are closely connected to personal circumstances, relationships, and future plans. A supportive decision-making process may help patients communicate what matters to them alongside clinical considerations. The supplied sources do not provide direct patient accounts or measured outcomes for a specific tool, so its real-world impact remains an open question.